journal
MENU ▼
Read by QxMD icon Read
search

Breast: Official Journal of the European Society of Mastology

journal
https://www.readbyqxmd.com/read/28732325/epidemiology-and-pathophysiology-of-pregnancy-associated-breast-cancer-a-review
#1
REVIEW
Rossana Ruiz, Carmen Herrero, Kathrin Strasser-Weippl, Diego Touya, Jessica St Louis, Alexandra Bukowski, Paul E Goss
The interactions between pregnancy and breast cancer (BC) are complex. Overall, parity is associated with long-term protective effects against BC, however in a small group of susceptible patients, pregnancy can lead to the development of a form of BC with a particularly poor prognosis. Pregnancy-associated breast cancer (PABC) remains an under-studied but important and growing clinical problem worldwide. Several aspects of PABC, including risk factors and mechanisms involved in its occurrence and aggressiveness, are incompletely understood...
July 18, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28732324/anti-m%C3%A3-llerian-hormone-amh-levels-in-premenopausal-breast-cancer-patients-treated-with-taxane-based-adjuvant-chemotherapy-a-translational-research-project-of-the-success-a-study
#2
E K Trapp, J Steidl, B Rack, M S Kupka, U Andergassen, J Jückstock, A Kurt, T Vilsmaier, A de Gregorio, N de Gregorio, M Tzschaschel, C Lato, A Polasik, H Tesch, A Schneeweiss, M W Beckmann, P A Fasching, W Janni, V Müller
BACKGROUND: Premenopausal women undergoing chemotherapy are at high risk for premature ovarian failure and its long-term consequences. Data on potential markers to evaluate ovarian reserve pre- and posttreatment are limited. Anti-Müllerian hormone (AMH) known for ovarian reserve in reproductive medicine could be a surrogate marker and was assessed in premenopausal breast cancer patients of the SUCCESS A study (EUDRA-CT no. 2005-000490-21). METHODS: We identified 170 premenopausal patients, age ≤ 40 years at trial entry, who received FEC-Doc as taxane-anthracylince based chemotherapy...
July 18, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28719811/risk-of-secondary-malignancies-after-radiation-therapy-for-breast-cancer-comprehensive-results
#3
Lindsay M Burt, Jian Ying, Matthew M Poppe, Gita Suneja, David K Gaffney
GOALS: To assess risks of secondary malignancies in breast cancer patients who received radiation therapy compared to patients who did not. METHODS: The SEER database was used to identify females with a primary diagnosis of breast cancer as their first malignancy, during 1973-2008. We excluded patients with metastatic disease, age <18 years, no definitive surgical intervention, ipsilateral breast cancer recurrence, or who developed a secondary malignancy within 1 year of diagnosis...
July 15, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28711793/efficacy-and-safety-of-everolimus-and-exemestane-in-hormone-receptor-positive-hr-human-epidermal-growth-factor-negative-her2-advanced-breast-cancer-patients-new-insights-beyond-clinical-trials-the-eva-study
#4
M E Cazzaniga, M Airoldi, V Arcangeli, S Artale, F Atzori, A Ballerio, G V Bianchi, L Blasi, S Campidoglio, M Ciccarese, M C Cursano, M Piezzo, A Fabi, L Ferrari, A Ferzi, C Ficorella, A Frassoldati, A Fumagalli, O Garrone, V Gebbia, D Generali, N La Verde, M Maur, A Michelotti, G Moretti, A Musolino, R Palumbo, M Pistelli, M Porpiglia, D Sartori, C Scavelli, A Schirone, A Turletti, M R Valerio, P Vici, A Zambelli, L Clivio, V Torri
BACKGROUND: The BOLERO-2 trial reported efficacy and safety of Everolimus (EVE) and Exemestane (EXE) combination in HR+ advanced breast cancer (ABC) patients. The BALLET trial further evaluated the safety of EVE-EXE in HR+ ABC patients, without reporting efficacy data. Aim of the EVA real-life study was to collect data of efficacy and safety of EVE-EXE combination in the clinical setting, as well as exploring efficacy according to EVE Dose-Intensity (DI) and to previous treatment with Fulvestrant...
July 13, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28709114/isolated-pachymeningeal-metastasis-from-breast-cancer-clinical-features-and-prognostic-factors
#5
Mi Hwa Heo, Yoo Jin Cho, Hee Kyung Kim, Ji-Yeon Kim, Yeon Hee Park
PURPOSE: To evaluate the clinical features and prognoses of patients with isolated pachymeningeal metastasis (IPM) from breast cancer. METHODS: We reviewed the medical records of all patients with metastatic breast cancer (MBC) treated from January 2009 to August 2016. Eligibility criteria included diagnosis of pachymeningeal metastasis based on brain magnetic resonance imaging and histologic diagnosis of primary breast cancer. We excluded patients with concomitant parenchymal or leptomeningeal metastases...
July 11, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28704698/interventional-radiology-in-breast-cancer
#6
REVIEW
Lizbeth Moira Kenny, Franco Orsi, Andreas Adam
Molecular profiling of metastatic disease may greatly influence the systemic therapy recommended by oncologists and chosen by patients, allowing treatment to be more targeted. Comprehensive care of patients with advanced breast cancer now includes percutaneous image-guided biopsy if this has the potential to influence systemic treatment [1]. Interventional radiologists can contribute significantly to the care of patients affected by breast cancer, in diagnostic and supportive procedures and importantly also in treatment...
July 10, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28704697/the-use-of-ultrasound-in-the-clinical-re-staging-of-the-axilla-after-neoadjuvant-chemotherapy-nact
#7
Anastasia Peppe, Robin Wilson, Romney Pope, Kate Downey, Jennifer Rusby
INTRODUCTION: Ultrasound (US) is the imaging modality of choice for staging the axilla prior to surgery in patients with breast cancer (BC). High pathological complete response rates in the axilla after NACT mean a more conservative approach to surgery can be considered. Radiological re-staging is important in this decision making. After the presentation of results from ACOSOG Z1071 in December 2012, formal ultrasound re-assessment of the axilla after primary therapy was specifically requested in our institution...
July 10, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28694015/predicting-treatment-resistance-and-relapse-through-circulating-dna
#8
Emma Beddowes, Stephen J Sammut, Meiling Gao, Carlos Caldas
The use of circulating DNA(ctDNA) to provide a non-invasive, personalised genomic snapshot of a patients' tumour has huge potential. Over the past five years this area of research has gained huge momentum. A number of studies in metastatic breast cancer have shown the potential of ctDNA to predict prognosis and treatment response using ctDNA. Further developments have included deeper sequencing using whole exome and shallow whole genome approaches which has the potential to identify new mutations and chromosomal copy number changes which appear upon resistance to treatment...
July 7, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28694014/de-escalating-and-escalating-systemic-therapy-of-early-breast-cancer
#9
Ian E Smith, Alicia F C Okines
No abstract text is available yet for this article.
July 7, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28694013/secondary-gastric-cancer-following-a-breast-cancer-diagnosis-beware-of-metastatic-breast-cancer
#10
LETTER
Pieter J Westenend
No abstract text is available yet for this article.
July 7, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28690105/de-escalating-and-escalating-systemic-therapy-in-triple-negative-breast-cancer
#11
Lisa A Carey
Triple negative breast cancer has the highest relapse risk of all the clinical subsets, although the escalation of chemotherapy has benefited this subset substantially over recent years. Systemic options are limited to chemotherapy, which makes meaningful de-escalation or escalation of therapy more challenging but possible. Observational cohorts suggest a less than 10% risk of relapse and minimal if any benefit of chemotherapy in very small (<1 cm), node-negative triple negative disease. In higher risk, particularly node-positive disease, anthracycline/taxane-based regimens remain standard...
July 7, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28690103/risk-communication-and-decision-making-in-the-prevention-of-invasive-breast-cancer
#12
Ann H Partridge
Risk communication surrounding the prevention of invasive breast cancer entails not only understanding of the disease, risks and opportunities for intervention. But it also requires understanding and implementation of optimal strategies for communication with patients who are making these decisions. In this article, available evidence for the issues surrounding risk communication and decision making in the prevention of invasive breast cancer are reviewed and strategies for improvement are discussed.
July 7, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28690107/preventing-invasive-breast-cancer-using-endocrine-therapy
#13
Mangesh A Thorat, Jack Cuzick
Developments in breast cancer treatment have resulted in reduction in breast cancer mortality in the developed world. However incidence continues to rise and greater use of preventive interventions including the use of therapeutic agents is needed to control this burden. High quality evidence from 9 major trials involving more than 83000 participants shows that selective oestrogen receptor modulators (SERMs) reduce breast cancer incidence by 38%. Combined results from 2 large trials with 8424 participants show that aromatase inhibitors (AIs) reduce breast cancer incidence by 53%...
July 6, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28690106/current-standards-in-oncoplastic-breast-conserving-surgery
#14
Walter P Weber, Savas D Soysal, Jasmin Zeindler, Elisabeth A Kappos, Doris Babst, Fabienne Schwab, Christian Kurzeder, Martin Haug
Oncoplastic breast conserving surgery is increasingly used to treat patients with breast cancer. In the absence of randomized data, a large body of observational evidence consistently indicates low rates of recurrence and high rates of survival, but points to a higher rate of complications compared to conventional breast conserving surgery. Established goals of oncoplastic breast conserving surgery are to broaden the indication for breast conservation towards larger tumors, and to improve esthetic outcomes...
July 6, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28690104/a-clinical-perspective-on-regional-nodal-irradiation-for-breast-cancer
#15
Amy C Moreno, Simona F Shaitelman, Thomas A Buchholz
The goal of regional treatments in breast cancer should be to eradicate any disease within lymph nodes, avoid regional recurrences, minimize the risk of distant metastases, and improve survival. In addition, regional treatments should focus on reducing potential morbidities and optimizing the long-term quality of life of breast cancer survivors. While data from recent surgical and radiation trials have helped clarify many issues regarding regional treatment, there still remains controversy as to the optimal approach for patients with "intermediate risk" disease...
July 6, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28689055/completeness-of-breast-cancer-operative-reports-in-a-community-care-setting
#16
Jordan Lang Eng, Christopher Ronald Baliski, Colleen McGahan, Eric Cai
OBJECTIVES: The narrative operative report represents the traditional means by which breast cancer surgery has been documented. Previous work has established that omissions occur in narrative operative reports produced in an academic setting. The goal of this study was to determine the completeness of breast cancer narrative operative reports produced in a community care setting and to explore the effect of a surgeon's case volume and years in practice on the completeness of these reports...
July 6, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28687441/de-escalation-of-treatment-in-her2-positive-breast-cancer-determinants-of-response-and-mechanisms-of-resistance
#17
Jamunarani Veeraraghavan, Carmine De Angelis, Jorge S Reis-Filho, Tomás Pascual, Aleix Prat, Mothaffar F Rimawi, C Kent Osborne, Rachel Schiff
Overexpression and/or gene amplification of HER2, a crucial member of the HER family of four receptors, occur in about 15-20% of breast cancers and define an aggressive subtype of the disease. Activated HER homo and heterodimers govern a complex and redundant downstream signaling network that regulates cell survival and metastasis. Despite treatment with effective HER2-targeted therapies, many HER2-positive tumors fail to respond, or initially respond but eventually develop resistance. One of the upfront reasons for this treatment failure is failure to accurately select the tumors that are truly dependent on HER2 for survival and so would benefit the most from HER2-targeted therapy...
July 4, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28676389/de-escalating-and-escalating-treatment-beyond-endocrine-therapy-in-patients-with-luminal-breast-cancer
#18
Amelia McCartney, Alessia Vignoli, Christopher Hart, Leonardo Tenori, Claudio Luchinat, Laura Biganzoli, Angelo Di Leo
Luminal breast cancers demonstrate significant molecular and clinical heterogeneity, despite the commonality of shared expression of the estrogen receptor (ER). To date, no clinical trial has prospectively investigated the optimal chemotherapy regime according to luminal type, highlighting a paucity of data furthermore required to guide treatment decisions. Current methods of predicting advantage from adjuvant chemotherapy lack refinement and can over-estimate the risk of relapse, inevitably leading to a proportion of patients being unnecessarily exposed to chemotherapy...
July 1, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28673539/trial-designs-and-results-supporting-treatment-de-escalation-and-escalation
#19
Meredith M Regan, William T Barry
Trials for escalation and de-escalation of treatment aim to improve patient care, but from different sides of the same coin with respect to disease control and burdens of treatment. De-escalation of therapy is inherently a non-inferiority question. A design with random assignment to standard of care versus de-escalated therapy is typically implemented but ordinarily will require a large sample size. Some research questions of treatment de-escalation might be asked in select patient populations using single-arm designs...
June 30, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28673538/tailoring-radiotherapy-according-to-cancer-subtypes
#20
Roberto Orecchia
Radiotherapy is able to improve locoregional control in breast cancer patients both after breast conserving surgery or mastectomy, with positive impact in high-risk patients for long-term survival. Recent advances in the precision of radiotherapy were based on the choice of the appropriate fractionation and technique. But the concept of adaptive radiotherapy is not only technical, and includes the biologic characterisation of the breast tumor. The knowledge that different subtypes of breast cancer can have distinct locoregional patterns of recurrence is consisted in the literature data...
June 30, 2017: Breast: Official Journal of the European Society of Mastology
journal
journal
31139
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"